memo inOncology Special Issue ESMO 2019
This report focuses on new advancements with checkpoint inhibition in non-small-cell lung cancer, the issue of optimal therapy across several lines for EGFR-mutant lung cancer as well as trial updates on frontline combinations of EGFR- and angiogenesis-targeted agents. Additionally, we discuss the synergy between anti-angiogenic drugs and immunotherapy as well as innovations in the setting of rare mutations. Further, you will find the latest updates on emerging survival benefits in the small-cell setting. One particular highlight is an interview with Stephen Liu talking about the importance of infrequent mutations in actionable driver genes.
Additionally, on our website, you will find expert video interviews with Filippo de Braud, Michael Duruisseaux, and Ioannis Metaxas on different conference highlights.
The memo inOncology Special Issue report is produced by Springer, as a supplement of memo (the Magazine of European Medical Oncology) and sponsored by Boehringer Ingelheim with an unrestricted educational grant. For more information on the memo inOncology Special Issue series, and for free access to all previous editions, visit the memo-inOncology website.